FDA issues alert about HIV drug Prezista

Mar 24, 2008

The U.S. Food and Drug Administration has issued an alert concerning reports of liver injury in patients taking Prezista.

The FDA said Prezista (darunavir), an anti-retroviral drug used to treat for the human immunodeficiency virus HIV, is suspected of contributing to several hepatic events, including liver failure, destruction of liver tissue, cirrhosis, hepatitis and jaundice.

Healthcare professionals were advised to conduct appropriate laboratory testing prior to and after starting patients on Prezista and to be alert for symptoms of hepatotoxicity, including unexplained fatigue, anorexia, nausea, jaundice, dark urine and liver tenderness.

Patients with chronic hepatitis B or C or those who have pretreatment elevations of liver function tests should be monitored more frequently.

The FDA said it worked with the drug's manufacturer -- Tibotec Therapeutics Inc. of Bridgewater, N.J. -- to include the new hepatotoxicity information on the drug's label.

Copyright 2008 by United Press International

Explore further: Taking a look at the dark side of tourism in the Dominican Republic

add to favorites email to friend print save as pdf

Related Stories

The remarkable simplicity of complexity

38 minutes ago

From the fractal patterns of snowflakes to cellular lifeforms, our universe is full of complex phenomena – but how does this complexity arise?

How to find the knowns and unknowns in any research

48 minutes ago

Have you ever felt overloaded by information? Ever wondered how to make sense of claims and counter-claims about a topic? With so much information out there on many different issues, how is a person new to ...

Recommended for you

More HIV+ patients undergoing spinal fusion

Sep 25, 2014

(HealthDay)—More HIV-positive patients are undergoing spinal fusions, and these patients have higher rates of complications resulting from the procedures, according to a study published in the Sept. 15 ...

User comments : 0